Newsroom

Stay up to date with what’s happening at ONO PHARMA USA.

Doctor meeting with a patient
Ono Enters into Collaboration Agreement with EVQLV to Generate Novel Antibodies against Multiple Targets Utilizing EVQLV’s AI-powered Antibody Design Engine for Development of Innovative Antibody Drugs
Press Release
December 19, 2023
ONO Selected for the DJSI World Index and DJSI Asia Pacific Index for Four Straight Years
Sustainability
December 12, 2023
Ono Expands Investment in Ono Venture Investment Fund I, L.P. to US$200 Million
Company
December 1, 2023
Ono Pharmaceutical Co., Ltd. Announced 2023 2Q Financial Results
Company
November 1, 2023
Ono Pharmaceutical Co., Ltd. Enters into a Drug Discovery Collaboration Agreement with Adimab to Discover Novel Antibody Drugs in the Oncology Field
Licensing
September 27, 2023
Ono Pharmaceutical Co., Ltd. Enters into a Drug Discovery Collaboration Agreement with Twist Bioscience to Discover Novel Antibodies for Autoimmune Diseases
Licensing
August 31, 2023
Ono Pharmaceutical Co., Ltd. Announced 2023 1Q Financial Results
Company
July 31, 2023
Ono Pharmaceutical Co., Ltd. Announced 2022 Full Year Financial Results
Company
May 10, 2023
ONO PHARMA USA Announces 2023 Golden Ticket Competition in Partnership with LabCentral and MBC BioLabs
Company
April 18, 2023
ONO PHARMA USA’s Tirabrutinib Receives Orphan Drug Designation from the FDA for the Treatment of Primary Central Nervous System Lymphoma
R & D
March 22, 2023